Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer

The combination of IMAGiC and iTILs as a biomarker can guide clinical decisions in the immunotherapy of metastatic TNBCs.

Authors

K. Paeng
Eun Yoon Cho (ORCID: https://orcid.org/0000-0003-4675-4492)
Kyoung‐Mee Kim (ORCID: https://orcid.org/0000-0002-1162-9205)
Shu Song
So Young Kang (ORCID: https://orcid.org/0000-0003-2142-2803)
Jin Seok Ahn (ORCID: https://orcid.org/0000-0002-2880-6730)
Han Gyeol Kim (ORCID: https://orcid.org/0000-0001-9228-2364)
Young‐Hyuck Im (ORCID: https://orcid.org/0000-0001-6459-8118)
Jiyeon Kim (ORCID: https://orcid.org/0000-0003-4566-4794)
Younghoon Lim (ORCID: https://orcid.org/0000-0002-6964-6788)
Yeonhee Park (ORCID: https://orcid.org/0000-0001-9537-1530)